Articles Companion animals

01 June 2026

Treatment of Canine Pemphigus Foliaceus, Pemphigus Vulgaris and Mucous Membrane Pemphigoid With Oclacitinib: A Retrospective Analysis of 21 Cases.

Clinical evidence update from Veterinary dermatology

Clinical Context

Peer-reviewed veterinary literature continues to shape everyday decision-making for canine patients, especially when new evidence clarifies diagnosis, treatment selection, monitoring, or clinical outcomes.

What the Study Evaluated

A study published in Veterinary dermatology in 2026 evaluated treatment of Canine Pemphigus Foliaceus, Pemphigus Vulgaris and Mucous Membrane Pemphigoid With Oclacitinib: A Retrospective Analysis of 21 Cases..

Key Findings

This study was performed to retrospectively evaluate the efficacy of oclacitinib (OC) (Apoquel; Zoetis) as a treatment option for pemphigus foliaceus (PF), pemphigus vulgaris (PV) and mucous membrane pemphigoid (MMP). To determine if OC can reduce or replace the corticosteroid use in dogs with PF, PV and MMP. There were no animal subjects. Multicentre retrospective study reviewing medical records from two institutions for dogs diagnosed with PF, PV or MMP and prescribed OC between 2014 and 2025. Twenty-one dogs diagnosed with PF, PV or MMP via histopathological results were included. OC alone was effective in eight of 18 PF dogs at a median...

Why It Matters for Veterinary Professionals

For veterinary professionals, the practical value of this work lies in how the findings may support more structured clinical assessment, clearer monitoring, and more informed decisions for canine patients.

Practical Interpretation

The results should be interpreted in the context of the study design, population, inclusion criteria, and clinical setting. Application in practice should consider patient-specific risk factors, available diagnostics, local standards of care, and clinician judgment.

Clinical Takeaway

Overall, the study adds useful evidence for clinicians seeking to align daily practice with current veterinary research while maintaining a balanced, case-by-case approach.

Read the full article here.

Like0

Dislike0

List
Add

Please enter a comment

Name *

Email address *

Comment *

* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @ grupoasis.com, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.

I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies

Dislike0

EVENTS

Edrapublishing

About Us Authors Contact Us Legal Notes Privacy Search

Top

Treatment of Canine Pemphigus Foliaceus, Pemphigus Vulgaris and Mucous Membrane Pemphigoid With Oclacitinib: A Retrospective Analysis of 21 Cases.

Clinical evidence update from Veterinary dermatology

Comments

List

Add

Tag

Related Articles

18 May 2026
Neurosurgery in canine epilepsy

Neurosurgery in canine epilepsy

13 May 2026
Undergrad researchers drive discovery in the College of Veterinary Medicine

Undergrad researchers drive discovery in the College of Veterinary Medicine

11 May 2026
African Swine Fever—How to Unravel Fake News in Veterinary Medicine

African Swine Fever—How to Unravel Fake News in Veterinary Medicine

27 April 2026
Orthopedic applications of 3D printing in canine veterinary medicine

Orthopedic applications of 3D printing in canine veterinary medicine

13 April 2026
Treatment of canine hip dysplasia

Treatment of canine hip dysplasia

More news

AASV Honors Dr. Robyn Fleck, V92 with the Technical Services/Allied Industry Veterinarian of the Year Award

Chewy Announces Participation in the J.P. Morgan 2026 Global Technology, Media and Communications Conference

Unlicensed antiviral products used for the at-home treatment of feline infectious peritonitis contain GS-441524 at significantly different amounts than advertised

Low-Invasive Biomarkers of Canine Mammary Tumours

Occurrence and Risk Factors of Brucellosis in Commercial Cattle Farms from Selected Districts of the Eastern Coast Zone, Tanzania

Newsletter

News of interest

Genotyping coronaviruses associated with feline infectious peritonitis

Two TVFS Vets and Two Fire Departments Rescue Horse Stuck in a Bog

The Rescued ‘Rebel’ that Inspired an Unending Scientific Legacy

Dog days: The experience of a clinical trial for a dog and his family

EVENTS